MRMohammadreza Rahmani

Mohammadreza Rahmani

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mohammadreza Rahmani has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Gervason Moriasi

    Department of Medical Biochemistry, School of Medicine, College of Health Sciences Mount Kenya University Thika Kenya

    1 shared publication
  • Ibrohim B. Sapaev

    Tashkent Institute of Irrigation and Agricultural Mechanization Engineers Tashkent Uzbekistan

    1 shared publication
  • Jitendra Gupta

    Institute of Pharmaceutical Research GLA University Mathura India

    1 shared publication
  • Marim Alwave

    Medical Technical College Al‐Farahidi University Baghdad Iraq

    1 shared publication
  • Maryam Golmohammadi

    School of Medicine Shahid Beheshti University of Medical Sciences Tehran Iran

    1 shared publication
  • Mazin A. A. Najm

    Pharmaceutical Chemistry Department, College of Pharmacy Al‐Ayen University Thi‐Qar Iraq

    1 shared publication

Latest Publications

  • Open Access

    Neuroprotective effects of resveratrol on retinal ganglion cells in glaucoma in rodents: A narrative review

    by Maryam Golmohammadi, Seyed Arash Aghaei Meibodi, Sulieman Ibraheem Shelash Al‐Hawary, Jitendra Gupta, Ibrohim B. Sapaev, Mazin A. A. Najm, Marim Alwave, Mozhgan Nazifi, Mohammadreza Rahmani, Mohammad Yasin Zamanian, et al.

    Glaucoma, an irreversible optic neuropathy, primarily affects retinal ganglion cells (RGC) and causes vision loss and blindness. The damage to RGCs in glaucoma occurs by various mechanisms, including elevated intraocular pressure, oxidative stress, inflammation, and other neurodegenerative processes. As the disease progresses, the loss of RGCs leads to vision loss. Therefore, protecting RGCs from damage and promoting their survival are important goals in managing glaucoma. In this regard, resveratrol (RES), a polyphenolic phytoalexin, exerts antioxidant effects and slows down the evolution and progression of glaucoma. The present review shows that RES plays a protective role in RGCs in cases of ischemic injury and hypoxia as well as in ErbB2 protein expression in the retina. Additionally, RES plays protective roles in RGCs by promoting cell growth, reducing apoptosis, and decreasing oxidative stress in H2O2‐exposed RGCs. RES was also found to inhibit oxidative stress damage in RGCs and suppress the activation of mitogen‐activated protein kinase signaling pathways. RES could alleviate retinal function impairment by suppressing the hypoxia‐inducible factor‐1 alpha/vascular endothelial growth factor and p38/p53 axes while stimulating the PI3K/Akt pathway. Therefore, RES might exert potential therapeutic effects for managing glaucoma by protecting RGCs from damage and promoting their survival.